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Abstract Trefoil factor family (TFF) peptides promote cell
migration, heal the mucosa and may suppress tumor growth. In
reporter gene assays we show that aspirin (1^12 mM) evokes a
six-fold up-regulation of TFF2, but not TFF1 and TFF3
transcription in human gastrointestinal cell lines. 6 h after
application up-regulation of endogenous TFF2 mRNA was
observed. TFF2 transcription was enhanced by indomethacin
and arachidonic acid but repressed by staurosporine, suggesting
mediation via protein kinase C. We mapped an aspirin
responding element 3546 to 3758 bp upstream of TFF2. Up-
regulation of TFF2 by aspirin may partially explain the
chemopreventive potential of low dose aspirin in gastrointestinal
carcinogenesis. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Peptides of the trefoil factor family (TFF) are characterized
by a conserved motif known as the trefoil domain. This do-
main consists of some 40 amino acid residues in which six
cysteines are disul¢de-linked forming a clover leaf structure
[1]. The conserved TFF domain is considered to interact with
glycosylated (mucin) molecules at mucous surfaces in verte-
brates. This idea is con¢rmed by recent results showing that
TFF-like domains are ancient motifs already existing in inver-
tebrates and that they are integrated in a variety of composed
proteins expressed at mucous surfaces [2]. The three human
TFF genes are clustered on chromosome 21q22.3 [3]. The
highest expression can be found in speci¢c epithelial cells of
the gastrointestinal tract. In vivo TFF1 is mainly transcribed
in the foveolar gastric cells [4], whereas TFF2 is found in the
deeper glands of the stomach and duodenum [5]. Expression
of TFF3 is fairly restricted to the goblet cells of the small and
large intestine [6].
Although the molecular mechanism of TFF function is still
unknown, results from several in vitro and in vivo studies
revealed the ability of TFFs to protect epithelia against ex-
perimentally induced mucosal damage [7^9]. Endogenous ex-
pression of TFF as well as recombinant TFFs stimulate cel-
lular motility, promote mucosal defense and wound healing
and inhibit tumor cell proliferation [10^13]. T¡1 knock-out
mice show aberrant gastric mucosa and develop gastric carci-
noma whereas T¡33=3 mice show impaired intestinal defence
[7,8].
Supporting their cytoprotective function, TFFs are up-regu-
lated in a variety of ulcerative, preneoplastic and neoplastic
conditions, or when the integrity of the mucosa is threatened
[3,11,14]. The regulation of these genes may be integrated into
the acute phase response, in£ammation and wound repair/res-
titution. In fact, we have recently demonstrated the activation
of TFF1 transcription by the transcription factor HNF-3,
which also activates other endodermal derived and acute
phase gene expression [15]. Moreover, the 5P-£anking region
of TFF1 contains several control elements responsive to estro-
gens, phorbol esters, c-Ha-ras, c-jun and other growth factors
[16].
On the one hand, long lasting administration of acetyl sal-
icylic acid (aspirin) is associated with gastric and intestinal
cancer chemoprevention [17,18]. On the other hand, this
widely used anti-in£ammatory drug is known to cause gastric
ulceration and damage. This drug inhibits the cyclooxygenase
(COX), the key enzyme of the proin£ammatory prostaglandin
biosynthesis. Recently, activation of genes for TFF2 and
COX-2 has been found during gastric adaptation to aspirin
damage in rats [19]. This prompted us to investigate whether
in human gastrointestinal cell lines in TFF gene regulation is
a¡ected by stimulation with aspirin. In this way we disclosed a
considerable modulation of TFF2 gene expression. Activation
of TFF2 transcription may be due to inhibition of the arachi-
donic acid metabolism. We suggest that aspirin may partially
exert its tumor preventive e¡ect by enhancement of the heal-
ing peptide TFF2 in vivo.
2. Materials and methods
2.1. Human cell lines and reporter plasmids
The poorly di¡erentiated gastric adenocarcinoma cell lines MKN45
and KatoIII as well as the colon adenocarcinoma cell line LS174T
were cultivated in RPMI1640 and DMEM supplemented with 20%
FCS or 10% FCS, respectively [20]. Luciferase reporter plasmid pGL3
(Promega) was used to construct TFF recombinants using the 5P-
£anking region of human TFF1 (position 31100 to +38), TFF2 (po-
sition 3821 to +61), and TFF3 (position 3867 to +63) [20,21]. TFF2
wild-type promoter (position 3821 bp to +61 bp) inserted into plas-
mid pGL3 was used for deletion mutagenesis by using the GeneEdi-
tor1 in vitro site-directed mutagenesis system (Promega) as described
[20,22]. All position numbers of the clones are displayed with respect
to the TATA box. All constructs were veri¢ed by DNA sequencing of
both strands.
2.2. Transient transfection assays
Cells grown to con£uence were trypsinized and seeded to nearly
30% of con£uence on 96-well plates the day before transfection. Tran-
sient transfection was performed by means of a liposome reagent
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E¡ectene (Qiagen, Hilden, Germany). 6 h after transfection, medium
was exchanged and a stock solution of acetyl salicylic acid, indome-
thacin, arachidonic acid and staurosporine (pH 7.5, purchased from
Sigma) was added to achieve the desired concentration. 40 h after
stimulation cells were lysed and luciferase assays were performed in
triplicates of quadruplicates. Renilla luciferase (pRL-CMV, Promega,
WI, USA) and dual luciferase measurements (Promega, #E1910) were
used to standardize transfection e⁄ciency and calculate speci¢c tran-
scriptional activity [20]. Results were expressed as ratio of ¢re£y lu-
ciferase to renilla luciferase and compared to the non-stimulated con-
trol (relative transcriptional activity). The standard deviation was less
than 15%. Each experiment was independently performed three times.
2.3. Multiplex RT-PCR and Northern blotting
Total cellular RNA was prepared and reverse transcribed using
oligo-dT primers. PCR primers were chosen from di¡erent exons to
exclude contamination with genomic DNA [23]. To ensure that PCR
was in the exponential phase, 22, 25 and 30 cycles of multiplex PCR
with TFF1+GAPDH+TFF2 or TFF1+GAPDH+TFF3 primer pools
were performed as described [22]. 15 Wg of cellular RNA were sub-
jected to Northern blotting. Blots were consecutively probed with
TFF2, GAPDH and TFF1 cDNA generated by PCR and labeled
by random priming using [32P-K]dCTP. Three independent experi-
ments revealed similar induction of TFF2 mRNA.
3. Results
3.1. E¡ect of aspirin on TFF reporter gene expression
To demonstrate the e¡ect of aspirin on the gene expression
of TFF peptides reporter gene analysis was performed in sev-
eral gastrointestinal cell lines. TFF2 transcription was up-
regulated in two gastric tumor cell lines, MKN45 and KatoIII
38 h after drug application (Fig. 1). At concentrations of
2.5 to 7 mM, a 6-fold transcriptional stimulation was ob-
served in MKN45 (Fig. 1A). A similar dose response was
also noticed in KatoIII (Fig. 1B). Higher concentrations of
aspirin (15 and 25 mM) resulted in a growth reduction of both
cell lines without any stimulation of TFF2 expression. We
observed a reduction of transcriptional activity after 2 days
at concentrations above 15 mM ASA and a loss of cell adhe-
sion after 3 days incubation above 25 mM ASA. Lower con-
centrations of aspirin (0.1 mM) showed no in£uence on the
TFF transcriptional activity at all. To investigate whether
stimulation by aspirin is a feature characteristic for all
TFFs, reporter gene analysis was carried out using TFF1,
TFF2 and TFF3 constructs in combination with the gastric
Fig. 1. E¡ect of acetylsalicylic acid (ASA) on the expression of
TFF2 reporter gene constructs. Luciferase expression was deter-
mined 38 h after ASA stimulation in gastric cell lines MKN45 (A)
and KatoIII (B) expressed in % of the non-stimulated control.
Fig. 2. E¡ect of ASA on the endogenous TFF mRNA expression in
MKN45. A: Multiplex RT-PCR assays using TFF1, TFF2 and
GAPDH oligos, following stimulation with 1, 2.5, and 10 mM ASA
or without ASA. B: Stimulation with 2 mM ASA for 3, 20 and 44
h. Even lanes display TFF1, TFF2 and GAPDH multiplex assays,
odd lanes display TFF1, TFF3 and GAPDH assays. C: Northern
blot from cells incubated with 2 and 7 mM ASA or without ASA
(0), for 6, 20 and 48 h, respectively.
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cell lines MKN45, KatoIII and the colon cell line LS174T
(Table 1). No considerable activation of TFF1 and TFF3
reporter gene expression was observed in all of the three cell
lines.
3.2. Aspirin stimulates endogenous TFF2 gene expression
As shown in previous studies, TFF reporter gene expression
resembles endogenous TFF gene expression in a variety of cell
lines [20]. To analyze whether aspirin also causes up-regula-
tion of endogenous TFF2 transcription, cells were cultivated
and stimulated under identical conditions as for reporter gene
analysis. Speci¢c mRNA levels of TFF1, TFF2, TFF3 and
GAPDH were determined after semi-quantitative multiplex
RT-PCR (Fig. 2A). In MKN45, application of aspirin pre-
ceded an increase of TFF2 mRNA, whereas neither TFF1
nor TFF3 mRNA were in£uenced (Fig. 2B). Up-regulation
of TFF2 mRNA was ¢rst detected 6 h after stimulation by
aspirin and reached its highest point after 20 h. Similar tran-
scriptional up-regulation of TFF2 was observed in multiplex
RT-PCR using L-actin as an internal standard (data not
shown). Northern blots revealed considerable induction of
TFF2 mRNA in cells 20 h and 48 h after stimulation by
aspirin con¢rming the results generated by RT-PCR (Fig.
2C, lanes 5, 6 and 8, 9).
3.3. Disturbance of the arachidonic acid metabolism stimulates
TFF2 expression
Indomethacin, a drug known to inhibit COX-1 was exam-
ined under similar conditions as aspirin to analyze the e¡ect
on TFF2 activation. In fact, doses known to inhibit COX-1
also promote a 2-fold up-regulation of TFF2 transcription
(Fig. 3A). To investigate whether an increased internal con-
centration of arachidonic acid, the physiological substrate of
COX-1, is responsible for TFF2 activation, arachidonic acid
was added to the cultivation medium. A 6-fold up-regulation
of TFF2 transcription was observed (Fig. 3B). Co-stimulation
of the MKN45 cells with arachidonic acid and ASA resulted
in a further increase of TFF2 transcription, but no additive
e¡ect was achieved. This indicates that arachidonic acid and
aspirin may in£uence the same signaling transduction path-
way. Since arachidonic acid is known to activate protein ki-
nase C, we furthermore treated MKN45 cells with staurospo-
rine, a protein kinase C inhibitor (Fig. 3C). This experiment
led to a 10-fold reduction of TFF2 reporter gene expression.
Simultaneous addition of ASA and staurosporine did not re-
verse the inhibitory e¡ect of staurosporine, but attenuated the
e¡ect, also indicating that a PKC pathway is involved in up-
regulation of TFF2 (see Fig. 5).
3.4. Localization of a TFF2 enhancing 5P-£anking region
In order to map a single cis-acting sequence motif respon-
sible for the aspirin e¡ect, various regions of the 5P-£anking
sequences of TFF2 were deleted. Thus, the reporter gene con-
structs were exposed to various concentrations of aspirin in
MKN45 cells (Fig. 4). In comparison to the TFF2 wild-type
reporter construct, deletions S546B, DM2 and DMyc resulted
in a 5^9-fold reduction of reporter gene expression, whereas
deletions DG6 and D3 still respond to aspirin. This indicates
an aspirin responding element located 546 to 758 bp upstream
to the TATA box.
4. Discussion
In our study we have shown that transcription of TFF2 is
up-regulated by administration of acetylsalicylic acid (ASA)
especially at concentrations between 2.5 and 7 mM in gastro-
intestinal cell lines. This was monitored by reporter gene ex-
pression and endogenous gene expression using RT-PCR
(Figs. 1 and 2). TFFs are gastrointestinal healing peptides
that trigger cell migration and restitution in vitro as well as
protecting and healing of experimentally induced ulceration in
rodents [9]. In addition, TFF1 may act as tumor suppressor,
since mice lacking TFF1 develop adenocarcinoma, and expres-
sion of TFF1 and TFF3 is down-regulated in gastrointestinal
Table 1
E¡ect of aspirin on TFF reporter gene expression
Cell line TFF1 TFF2 TFF3
MKN45 100 620 110
KatoIII 120 450 130
LS174T 160 270 180
Displayed in % of the control (not stimulated). S.E.M. was 9 15%
in triplicate experiments.
Fig. 3. E¡ect of indomethacin (A), arachidonic acid (B) and stauro-
sporine (C) on the expression of TFF2 reporter genes in MKN45.
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cancers [7]. Although TFF33=3 mice do not develop colon
cancer, overexpression of TFF3 has been shown to inhibit
colon tumor cell proliferation in vivo and in vitro [13].
TFF2 may also suppress tumor growth, since recombinant
TFF2 substitutes the cytoprotective function of TFF1 and
TFF3 [9,10,12,28].
The widely used drug aspirin is known to have harmful side
e¡ects leading to gastric lesion and ulceration. However, epi-
demiological data, animal models and clinical studies all sug-
gest that aspirin or other non-steroidal anti-in£ammatory
drugs (NSAIDs) are potent preventive agents for colon cancer
[18] and there is also recent evidence that regular aspirin users
are at reduced risk of gastric and esophageal cancer [24,25].
One putative biochemical target of the cancer chemopreven-
tive activity of aspirin is cyclooxygenase (COX) inhibition.
ASA is reported to inhibit both cyclooxygenases with a pref-
erence for COX-1 (IC80 = 8 WM) over COX-2 (IC80 = 30 WM)
[26]. However, reports of chemopreventive activity of NSAID
derivatives lacking COX inhibition suggest that there are oth-
er biochemical targets as well [27].
There is recent evidence that TFF2 activation by aspirin
also occurs in vivo. In the stomach of rats, the application
of ASA leads to activation of TFF2 after 24 h [19]. The acti-
vation in vivo as well as the up-regulation of TFF2 in vitro
may be explained by the same molecular mechanisms. Thus
our in vitro system may provide an interesting model to ex-
plain some observations in vivo. The concentration of ASA
(2.5 mM) that activates TFF2 in vitro, is also reached in the
human gastric lumen after intake of 100 mg of aspirin. This
suggests that TFF2 activation also occurs in many individuals
who use this drug e.g. for prevention of cardiovascular dis-
ease. Whether TFF2 activation is the relevant molecular key-
player for the observed gastric chemopreventive e¡ect of as-
pirin remains to be proven. In rodents and in vitro, however,
gastrointestinal cytoprotection through administration of re-
combinant TFF2 peptide is well established [9,10,12,28].
In KatoIII and MKN45, we observed a TFF2 up-regulation
between 2 and 8 mM and growth reduction and loss of adher-
ence to plastic surface between 15 and 25 mM. In vivo, the
chemopreventive and the detrimental (ulcerative) e¡ect of as-
pirin may also be within a small dose response range.
Various experiments were performed to elucidate the mo-
lecular mechanism of TFF2 activation by aspirin. Although
several signaling cascades may be involved we favor the model
displayed in Fig. 5: Aspirin inhibits COX-1 raising up the
intracellular level of arachidonic acid. This would activate
protein kinase C eventually modifying (directly or indirectly)
Fig. 4. Localization of the 5P-£anking region of TFF2 responsible for aspirin activation. Various reporter gene constructs are tested for their
ability to respond to di¡erent ASA concentrations. For each construct the e¡ect of aspirin is displayed in % of transcriptional activity relative
to the control.
Fig. 5. Proposed signal transduction pathway leading to transcrip-
tional up-regulation of TFF2.
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transcription factors acting on elements of the 5P-£anking re-
gion of TFF2.
Our model that COX-1 inhibition is the primary target of
the aspirin response is based on the observation that COX-1
but not COX-2 transcription occurs in our MKN45 cell lines
(performed by RT-PCR, unpublished results). Moreover in-
domethacin, another COX-1 inhibitor, causes up-regulation of
TFF2 (Fig. 3A) at doses known to speci¢cally a¡ect COX-1
[29]. Addition of arachidonic acid ^ the physiological sub-
strate of COX-1 ^ also leads to a 6-fold enhancement of
TFF2 transcription. Furthermore, we found no additive e¡ect
after co-stimulation of MKN45 cells with arachidonic acid
and ASA. This indicates that arachidonic acid and aspirin
in£uence the same signal transduction pathway. Arachidonic
acid is known to activate protein kinase C (PKC) [30]. There-
fore, inhibition of PKC by staurosporine should lead to a
marked reduction in TFF2 transcription. Indeed, staurospo-
rine treatment resulted in a 10-fold reduction of TFF2 tran-
scription as displayed in Fig. 3C. Moreover, addition of ASA
did not reverse the inhibitory e¡ect of staurosporine, also
indicating that a PKC pathway is involved in up-regulation
of TFF2.
Finally, using deletion analysis on TFF2 reporter con-
structs, we mapped enhancing elements on the 5P-£anking
region of TFF2 responsible for the up-regulation by aspirin.
Several deletion constructs were impaired in their ability to
respond to aspirin. The smallest overlapping region causing a
severe transcriptional reduction is located between 3758 and
3546 bp upstream to the TATA box (Fig. 4). This region
does not cover binding sites for transcription factors HNF-3
and GATA-6 that we showed to activate TFF2 transcription
[15,22] and therefore likely represents a new enhancing ele-
ment.
Taken together, our results suggest that in gastric cell lines
aspirin is able to activate transcription of TFF2 coding for a
gastrointestinal healing peptide. We speculate that in vivo,
transcriptional activation of TFF2 as well as other genes
may provide an explanation for the chemopreventive activity
of this widely used drug.
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